查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511925

个人化医疗市场规模、份额、趋势分析报告：按产品、最终用途、地区、细分市场预测，2024-2030 年

Personalized Medicine Market Size, Share & Trends Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

个人化医疗市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球个人化医疗市场规模将达到9,098亿美元，2024年至2030年复合年增长率为8.20%。由于疾病发生率的增加和对新型疗法的需求不断增加，预计 2023 年至 2030 年该市场的复合年增长率将达到 7.20%。巨大的研究努力不断增强个人化医疗的新兴应用。例如，2022 年 7 月，麻省大学陈年医学院的研究人员将使用基于微生物的个人化来帮助了解代谢变异，以测量个别基因组、饮食、微生物组和相关环境因素之间的关联。

大多数癌症是由基因不匹配引起的，如果进展可能致命。了解特定的基因组特征可以有效、精确地治疗癌症。例如，2020 年 5 月，Qiagen 推出了 QIAseq 泛癌症多模式面板，旨在分析癌症受试者的基因组特征，为固体癌和血红素恶性的分析提供广泛的精准医学应用。

NGS 技术的进步和对人类基因组的广泛研究积极推动了该市场。人们越来越有兴趣利用 NGS 来获得可用于治疗癌症和罕见遗传疾病的个人化医疗结果。例如，Illumina 宣布将在巴黎举行的欧洲肿瘤学会 (ESMO) 年会上展示多项肿瘤学研究的摘要。 Illumina 的研究透过切片检查的全面基因组分析将受试者与潜在的药物和免疫疗法相匹配，从而实现个人化癌症治疗。

远端医疗透过虚拟方式或透过电话提供临床建议，以补充物理上的便利性。远端医疗日益流行，特别是自 COVID-19 大流行以来。各国政府和研究机构正大力加强个人化远端医疗的应用。例如，2022 年 8 月，美国国家癌症美国宣布提供 2,300 万美元的五年津贴，支持在美国各地推出远距医疗卓越远端医疗中心 (TRACE)。

分子影像系统和医疗设备在个人化医疗的新进展中发挥着重要作用。分子影像系统和医疗设备正在有效地利用个人化医疗的应用来治疗各种类型的癌症。例如，2022 年 6 月，GE Healthcare 宣布使用镓 68 放射性同位素进行高端分子成像，用于前列腺癌诊断和监测。

由于新技术的进步以及联盟和业务扩张等持续的行业努力，市场正处于成长阶段。例如，2021 年 12 月，Biogen Inc. 和 TheraPanacea 宣布建立合作关係，专注于推广神经科学个人化医疗的数位健康。

个性化医疗市场报告亮点

  • 该市场的整体成长是由于对利用基因层面的疾病所了解的新型疗法的不断增长的需求以及全球癌症和遗传疾病发病率的上升所推动的。
  • 由于药物基因组学在生物製药开发中的广泛应用，个人化医疗治疗领域预计将在预测期内实现高速成长。此外，由于全基因组定序成本大幅下降，预计基因组治疗领域在预测期内将显着成长。
  • 由于主要企业的存在以及对新疗法开发的深入研究以寻找各种疾病的治疗方法，北美将在 2023 年占据市场主导地位。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章个人化医疗市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 个人化药品市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章个人化医疗市场：产品评估与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 按产品分類的全球个人化医疗市场前景
  • 2018-2030年市场规模、预测及趋势分析

第五章个人化医疗市场：最终用途估计与趋势分析

  • 2023年及2030年市场占有率方法
  • 细分仪表板
  • 按最终用途分類的全球个人化医疗市场展望
  • 2018-2030年市场规模、预测及趋势分析

第六章个人化医疗市场：区域估算与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • GE Healthcare
    • Illumina, Inc.
    • ASURAGEN, INC.
    • Abbott
    • Dako A/S
    • Exact Sciences Corporation
    • Danaher Corporation（Cepheid, Inc.）
    • Decode Genetics, Inc.
    • QIAGEN
    • Exagen Inc.
    • Precision Biologics
    • Celera Diagnostics LLC
    • Biogen
    • Genelex
    • IBM
    • Genentech, Inc.
    • 23andMe, Inc.
Product Code: 978-1-68038-443-7

Personalized Medicine Market Growth & Trends:

The global personalized medicine market size is expected to reach USD 909.80 billion by 2030, expanding at a CAGR of 8.20% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 7.20% from 2023 to 2030 owing to the increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual's genome, diet, microbiota, and associative environmental factors.

Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.

The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.

Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.

Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.

The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.

Personalized Medicine Market Report Highlights:

  • The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe
  • The personalized medicine therapeutics segment is anticipated to witness high growth over the forecast period owing to the extensive usage of pharmacogenomics for developing biopharmaceuticals. Further, the genomic medicine therapeutics segment is anticipated to grow substantially during the forecast period owing to significantly lowered costs of whole-genome sequencing
  • North America dominated the market in 2023 due to the presence of key players and their intensive research for the development of novel therapies to find out curative solutions for various diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End-use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Personalized Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advancements in next-generation sequencing technology
      • 3.2.1.2. Expanding portfolio of companion/associated diagnostics
      • 3.2.1.3. Increasing prevalence of cancer & usage of biomarkers for personalized medicine cancer therapy
      • 3.2.1.4. Technological advancements to facilitate R&D for personalized medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Presence of nonvalue-based personalized medicine diagnostics reimbursement policy
      • 3.2.2.2. Lack of proper intellectual property regulations for personalized medical technologies
  • 3.3. Personalized Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Personalized Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Personalized Medicine Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Personalized Medicine Diagnostics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.2. Genetic Testing
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.3. DTC Diagnostics
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.4. Esoteric Lab Services
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.1.5. Esoteric Lab Tests
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Personalized Medicine Therapeutics
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.2.2. Pharmaceutical
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.2.3. Genomic Medicine
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.2.4. Medical Devices
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Personalized Medical Care
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.2. Telemedicine
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.3. Health Information Technology
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Personalized Nutrition & Wellness
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.4.2. Retail Nutrition
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.4.3. Complementary & Alternative Medicine
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Personalized Medicine Market: End-use Estimates & Trend Analysis

  • 5.1. Method Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Personalized Medicine Market by End-use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Academic & Research Institutes
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. Diagnostic Centers
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Personalized Medicine Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. GE Healthcare
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Illumina, Inc.
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. ASURAGEN, INC.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Abbott
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Dako A/S
      • 7.3.8.1. Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Product Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Exact Sciences Corporation
      • 7.3.9.1. Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Product Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Danaher Corporation (Cepheid, Inc.)
      • 7.3.10.1. Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Product Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. Decode Genetics, Inc.
      • 7.3.11.1. Overview
      • 7.3.11.2. Financial Performance
      • 7.3.11.3. Product Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. QIAGEN
      • 7.3.12.1. Overview
      • 7.3.12.2. Financial Performance
      • 7.3.12.3. Product Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. Exagen Inc.
      • 7.3.13.1. Overview
      • 7.3.13.2. Financial Performance
      • 7.3.13.3. Product Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. Precision Biologics
      • 7.3.14.1. Overview
      • 7.3.14.2. Financial Performance
      • 7.3.14.3. Product Benchmarking
      • 7.3.14.4. Strategic Initiatives
    • 7.3.15. Celera Diagnostics LLC
      • 7.3.15.1. Overview
      • 7.3.15.2. Financial Performance
      • 7.3.15.3. Product Benchmarking
      • 7.3.15.4. Strategic Initiatives
    • 7.3.16. Biogen
      • 7.3.16.1. Overview
      • 7.3.16.2. Financial Performance
      • 7.3.16.3. Product Benchmarking
      • 7.3.16.4. Strategic Initiatives
    • 7.3.17. Genelex
      • 7.3.17.1. Overview
      • 7.3.17.2. Financial Performance
      • 7.3.17.3. Product Benchmarking
      • 7.3.17.4. Strategic Initiatives
    • 7.3.18. IBM
      • 7.3.18.1. Overview
      • 7.3.18.2. Financial Performance
      • 7.3.18.3. Product Benchmarking
      • 7.3.18.4. Strategic Initiatives
    • 7.3.19. Genentech, Inc.
      • 7.3.19.1. Overview
      • 7.3.19.2. Financial Performance
      • 7.3.19.3. Product Benchmarking
      • 7.3.19.4. Strategic Initiatives
    • 7.3.20. 23andMe, Inc.
      • 7.3.20.1. Overview
      • 7.3.20.2. Financial Performance
      • 7.3.20.3. Product Benchmarking
      • 7.3.20.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 3 North America Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 4 North America Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 7 Canada Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 8 Canada Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 9 Europe Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 11 Europe Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 12 France Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 13 France Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 14 Germany Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 15 Germany Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 16 UK Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 17 UK Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 18 Spain Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 19 Spain Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 20 France Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 21 France Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 22 Italy Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 23 Italy Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 24 Sweden Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 25 Sweden Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 26 Norway Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 27 Norway Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 28 Denmark Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 29 Denmark Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 31 Asia Pacific Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 32 Asia Pacific Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 33 Japan Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 34 Japan Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 35 China Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 36 China Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 37 India Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 38 India Personalized Medicine Market, By End-Use, 2018 - 2030 (USD Billion)
  • Table 39 South Korea Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 South Korea Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 41 Australia Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 42 Australia Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 43 Thailand Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 44 Thailand Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 45 Latin America Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 46 Latin America Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 47 Latin America Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 48 Brazil Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 49 Brazil Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 50 Mexico Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 51 Mexico Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 52 Argentina Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 53 Argentina Personalized Medicine Market, By End-Use, 2018 - 2030 (USD Billion)
  • Table 54 MEA Personalized Medicine Market, By Country, 2018 - 2030 (USD Billion)
  • Table 55 MEA Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 56 MEA Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 57 South Africa Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 58 South Africa Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 59 Saudi Arabia Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 61 UAE Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 62 UAE Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)
  • Table 63 Kuwait Personalized Medicine Market, By Product, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait Personalized Medicine Market, By End-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Personalized medicine market segmentation
  • Fig. 8 Market snapshot, 2023
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 PESTEL analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global personalized medicine market, for product, 2018 - 2030 (USD Billion)
  • Fig. 15 Global personalized medicine market, for diagnostics, 2018 - 2030 (USD Billion)
  • Fig. 16 Global personalized medicine market, for genetic testing, 2018 - 2030 (USD Billion)
  • Fig. 17 Global personalized medicine market, for direct-to-consumer (DTC) testing, 2018 - 2030 (USD Billion)
  • Fig. 18 Global personalized medicine market, for esoteric lab services, 2018 - 2030 (USD Billion)
  • Fig. 19 Global personalized medicine market, for esoteric lab tests, 2018 - 2030 (USD Billion)
  • Fig. 20 Global personalized medicine market, for therapeutics, 2018 - 2030 (USD Billion)
  • Fig. 21 Global personalized medicine market, for pharmaceutical, 2018 - 2030 (USD Billion)
  • Fig. 22 Global personalized medicine market, for genomic medicine, 2018 - 2030 (USD Billion)
  • Fig. 23 Global personalized medicine market, for medical devices, 2018 - 2030 (USD Billion)
  • Fig. 24 Global personalized medicine market, for personalized medical care, 2018 - 2030 (USD Billion)
  • Fig. 25 Global personalized medicine market, for telemedicine, 2018 - 2030 (USD Billion)
  • Fig. 26 Global personalized medicine market, for health information technology, 2018 - 2030 (USD Billion)
  • Fig. 27 Global personalized medicine market, for personalized nutrition & wellness, 2018 - 2030 (USD Billion)
  • Fig. 28 Global personalized medicine market, for retail nutrition, 2018 - 2030 (USD Billion)
  • Fig. 29 Global personalized medicine market, for complementary & alternative medicine, 2018 - 2030 (USD Billion)
  • Fig. 30 Global personalized medicine market, for End-use, 2018 - 2030 (USD Billion)
  • Fig. 31 Global personalized medicine market, for diagnostics centers, 2018 - 2030 (USD Billion)
  • Fig. 32 Global personalized medicine market, for academic and research institutes, 2018 - 2030 (USD Billion)
  • Fig. 33 Global personalized medicine market, for hospitals, 2018 - 2030 (USD Billion)
  • Fig. 34 Global personalized medicine market, for others, 2018 - 2030 (USD Billion)
  • Fig. 35 Regional outlook, 2023 & 2030
  • Fig. 36 North America personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 37 U.S. personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 38 Canada personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 39 Europe personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 40 Germany personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 41 UK personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 42 France personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 43 Italy personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 44 Spain personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 45 Denmark personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 46 Sweden personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 47 Norway personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 48 Asia Pacific personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 49 Japan personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 50 China personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 51 India personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 52 Australia personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 53 Thailand personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 54 South Korea personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 55 Latin America personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 56 Brazil personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 57 Mexico personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 58 Argentina personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 59 MEA personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 60 South Africa personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 61 Saudi Arabia personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 62 UAE personalized medicine market, 2018 - 2030 (USD Billion)
  • Fig. 63 Kuwait personalized medicine market, 2018 - 2030 (USD Billion)